** H.C. Wainwright initiates coverage of drug developer Galectin Therapeutics GALT.O with 'buy' rating; sets PT at $6, which is ~233.3% upside on stock's last close
** Brokerage says Galectin is currently developing belapectin to treat chronic liver disease called metabolic dysfunction-associated steatohepatitis (MASH), which can progress to cirrhosis, liver failure and liver cancer
** H.C. Wainwright says GALT's belapectin is only therapy in development for MASH cirrhosis
** "Initial clinical trials exhibited compelling trends towards preventing and halting signs and symptoms of the disease," brokerage says
** Including session's moves, stock up ~45% YTD
(Reporting by Prakhar Srivastava in Bengaluru)
((Prakhar.srivastava2@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.